Integrating an INTEGRA VIAFLO 96 multichannel pipette into their high throughput expression facility has enabled Molecular Partners (Zurich, Switzerland) to streamline the discovery and development of a novel class of targeted protein therapeutics termed DARPins.
DARPins are a next generation of protein therapeutics combining the advantages of antibodies and small molecule drugs. High target specificity and potency, small size, cost-effective production and a whole range of possible multi-specific format choices gives them the potential to surpass existing antibody drugs and revolutionize protein therapeutics.
Andreas Lehmann, an Expert Technical Assistant working in Molecular Partners 96-well high throughput expression facility commented “Our lab is extremely satisfied with our decision to purchase and incorporate INTEGRA’s VIAFLO 96 into our development protocols. The main application we are using the system for currently is protein purification using IMAC (Immobilized Metal Affinity Chromatography). The VIAFLO 96 is used for various steps in the process starting from ...
